CN113797155B - 一种不可溶的透皮微针贴片及其制备方法和应用 - Google Patents
一种不可溶的透皮微针贴片及其制备方法和应用 Download PDFInfo
- Publication number
- CN113797155B CN113797155B CN202111073707.1A CN202111073707A CN113797155B CN 113797155 B CN113797155 B CN 113797155B CN 202111073707 A CN202111073707 A CN 202111073707A CN 113797155 B CN113797155 B CN 113797155B
- Authority
- CN
- China
- Prior art keywords
- microneedle
- sodium alginate
- solution
- transdermal
- microneedle patch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 79
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 79
- 239000000661 sodium alginate Substances 0.000 claims abstract description 79
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 79
- 239000000758 substrate Substances 0.000 claims abstract description 13
- 239000000243 solution Substances 0.000 claims description 80
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 claims description 20
- 238000004132 cross linking Methods 0.000 claims description 20
- 235000012209 glucono delta-lactone Nutrition 0.000 claims description 19
- 229960003681 gluconolactone Drugs 0.000 claims description 19
- UEAVLBXLOZNDHT-UHFFFAOYSA-K calcium;sodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].[Ca+2].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEAVLBXLOZNDHT-UHFFFAOYSA-K 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 239000007864 aqueous solution Substances 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 15
- 239000003431 cross linking reagent Substances 0.000 claims description 13
- 238000011065 in-situ storage Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 7
- 239000013543 active substance Substances 0.000 claims description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000003361 porogen Substances 0.000 claims description 4
- 238000001647 drug administration Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 claims description 2
- 229920000858 Cyclodextrin Polymers 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- 241000289690 Xenarthra Species 0.000 claims description 2
- RXDLGFMMQFNVLI-UHFFFAOYSA-N [Na].[Na].[Ca] Chemical compound [Na].[Na].[Ca] RXDLGFMMQFNVLI-UHFFFAOYSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 claims description 2
- 239000001099 ammonium carbonate Substances 0.000 claims description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 2
- SHWNNYZBHZIQQV-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-L 0.000 claims description 2
- 229940113960 edetate calcium Drugs 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000002639 sodium chloride Nutrition 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000013271 transdermal drug delivery Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 37
- 229940079593 drug Drugs 0.000 abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 15
- 230000008961 swelling Effects 0.000 abstract description 13
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 238000009825 accumulation Methods 0.000 abstract description 3
- 230000002503 metabolic effect Effects 0.000 abstract description 3
- 239000011148 porous material Substances 0.000 abstract description 2
- 239000002195 soluble material Substances 0.000 abstract description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 24
- 239000012498 ultrapure water Substances 0.000 description 24
- 210000003491 skin Anatomy 0.000 description 22
- 230000007794 irritation Effects 0.000 description 15
- 238000007664 blowing Methods 0.000 description 12
- 239000000843 powder Substances 0.000 description 12
- 230000007480 spreading Effects 0.000 description 12
- 238000003892 spreading Methods 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 8
- 229910021421 monocrystalline silicon Inorganic materials 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 5
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 5
- 229960005070 ascorbic acid Drugs 0.000 description 5
- 230000001186 cumulative effect Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229930014456 matrine Natural products 0.000 description 5
- 229960000401 tranexamic acid Drugs 0.000 description 5
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 5
- 239000002211 L-ascorbic acid Substances 0.000 description 4
- 235000000069 L-ascorbic acid Nutrition 0.000 description 4
- 238000002073 fluorescence micrograph Methods 0.000 description 4
- 206010040880 Skin irritation Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- VEUACKUBDLVUAC-UHFFFAOYSA-N [Na].[Ca] Chemical compound [Na].[Ca] VEUACKUBDLVUAC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 239000004083 gastrointestinal agent Substances 0.000 description 1
- 229940127227 gastrointestinal drug Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0023—Drug applicators using microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0046—Solid microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0053—Methods for producing microneedles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
- A61M37/0015—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin by using microneedles
- A61M2037/0061—Methods for using microneedles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
本发明公开了一种不可溶的透皮微针贴片,包括:微针,该微针包含基底以及位于基底上的针尖,且所述微针主要由交联的海藻酸钠构成;背衬,与所述基底相结合,且所述背衬中与针尖相对应的部分为镂空部。该微针贴片可长时间作用于皮肤,且其用于透皮给药时,药物可通过作用于皮肤上的溶胀的微针吸水后的孔道,进入皮肤微孔吸收至体内,由此增加药物在透皮给药时的生物利用度。在给药结束后,微针可被完整地取出,不会增加体内的代谢负担,并且避免了可溶材料在体内蓄积,具有良好生物安全性。本发明还公开了该微针贴片的制备方法和应用。
Description
技术领域
本发明涉及医药技术领域。更具体地,涉及一种不可溶的透皮微针贴片及其制备方法和应用。
背景技术
经皮给药是一种常见的给药方式,可改善患者依从性,同时避免胃肠道药物分解,提高生物利用度,并消除皮下注射带来的疼痛。角质层的存在从药物分子量和药物水溶性限制其适用范围,仅少数药物可以通过透皮方式进行给药,且给药效率有限。近年来随着微纳加工技术的发展,微针给药的研究进程被快速推进。微针阵列是一种微创设备,可以无痛地穿过皮肤角质层,辅助药物在经皮给药途径中穿过屏障,提高药物的生物利用度。微针具有可批量生产,成本低廉,适用药物众多,患者可自主给药等优点,近年来受到了广泛的关注。
微针的研究众多,以微针的溶解性能可分为溶解微针和不可溶解微针。溶解微针在应用于临床前,需要对可溶解于皮内的成分进行代谢和消除途径的研究,判断材料的生物安全性,由此会不可避免地延迟商业化进程。不可溶解微针多由金属,单晶硅或高分子为材料组成,微针在应用于皮肤后可被完整地移除,在体内不产生材料蓄积并减轻材料代谢负担。由此,目前在临床应用中仍以不可溶解微针为主。常用的不可溶微针在辅助药物透皮时,需要在微针移除后涂抹或敷贴药物,使药物通过微针形成的皮肤孔道。皮肤上的微孔道在移除微针时开始愈合,微针孔道的存留时间受皮肤自修复的限制,使药物透皮吸收的整体效率难以得到进一步提升。
发明内容
本发明的第一个目的在于提供一种不可溶的透皮微针贴片,该透皮微针贴片中不含活性物质,且施药后,在移除该透皮微针贴片后,无需再涂抹或敷贴药物促进药物的吸收即可获得好的生物利用度。
本发明的第二个目的在于提供一种不可溶的透皮微针贴片的制备方法。
本发明的第三个目的在于提供一种不可溶的透皮微针贴片的应用。
为达到上述第一个目的,本发明采用下述技术方案:
一种不可溶的透皮微针贴片,包括:
微针,该微针包含基底以及位于基底上的针尖,且所述微针主要由交联的海藻酸钠构成;
背衬,与所述基底相结合,且所述背衬中与针尖相对应的部分为镂空部。
该透皮微针贴片中,基底和针尖可一体成型,也可分别成型,具体可根据不同的工艺进行选择。此外,该微针主要由交联的海藻酸钠构成,可以理解成该微针的主体部分为交联的海藻酸钠。
进一步地,所述交联的海藻酸钠为由海藻酸钠与原位交联剂交联而成的结构。采用该体系得到的交联的海藻酸钠作为微针主体不仅具有较高的强度,能很好的施加于皮肤内;同时,其对皮肤无刺激,安全无害;此外,该交联的海藻酸钠具有较高的溶胀度,能很好的将活性物质给入皮下,具有高的生物利用度;最后,该微针不溶于水,给药时,可随取随停,能很好的控制给药量。
进一步地,所述交联的海藻酸钠由海藻酸钠水溶液与原位交联剂的水溶液混合成均匀的水溶液后,交联而成。
进一步地,所述原位交联剂为依地酸钙钠和葡萄糖酸内酯的混合;其中,所述依地酸钙钠与葡萄糖酸内酯的摩尔比为1:0.8~1:1.2。在此条件下,制备得到的微针在保证具有高溶胀度的条件下,微针具有高的强度且皮肤刺激性更小。
进一步地,所述原位交联剂的水溶液中,依地酸钙钠的浓度为0.3-1.0mol/L。
进一步地,所述海藻酸钠水溶液与原位交联剂的水溶液的体积比为20:1~4:1。
进一步地,所述海藻酸钠水溶液的固含量为12-25%。
进一步地,所述原位交联剂中,葡萄糖酸内酯与异地酸钙钠摩尔比为0.8~1.2。
进一步地,所述微针中还包含致孔剂。致孔剂的存在有助于皮内水分子进入上段针尖基质内部,调控药物释放速率。
进一步地,所述致孔剂的添加量占微针总重量的0.1~10wt%。
进一步地,所述致孔剂选自氯化钠、碳酸钠、碳酸氢钠、碳酸氢铵、聚乙烯吡咯烷酮、透明质酸及其钠盐、纤维素类衍生物、海藻糖、麦芽糖、环糊精类中的一种或几种。
进一步地,背衬为背衬膜。背衬膜的选择以能够很好的与微针基底结合为准。
为达到上述第二个目的,本发明采用下述技术方案:
一种不可溶的透皮微针贴片的制备方法,包括如下步骤:
将海藻酸钠水溶液与原位交联剂的水溶液混合,形成均匀的混合液;
将该混合液置于微针模具上,抽真空,使溶液填充模具针孔的同时完成海藻酸钠交联,干燥;
将干燥后得到的微针从模具上取下,并将基底与背衬结合。
进一步地,所述干燥为吹风干燥,时间优选为20-40min。
进一步地,在注液成型时,根据交联剂的不同添加量,抽真空时间为15-30min。
为达到上述第三个目的,本发明采用下述技术方案:
一种不可溶的透皮微针贴片在透皮给药中的应用。
进一步地,该应用包括如下步骤:
将该透皮微针贴片的微针施加于人体皮肤内;
通过背衬的镂空部,向微针上施加活性物质;
待给药完毕,取出该透皮微针贴片,即可。
本发明中,活性物质可为药物、药物乳膏、药物凝胶等。其中、所述药物可为可溶性药物和不可溶性药物。不可溶性药物可为脂溶性药物如生育酚、抗真菌/细菌药物等;可溶性药物可为水溶酸性药物如L-抗坏血酸、水溶性中性药物如氨甲环酸、水溶性碱如苦参碱、多肽类药物如艾塞那肽、多糖类药物如肝素、核酸类药物如三氮唑核苷等。
本发明的有益效果如下:
本发明提供的不可溶的透皮微针贴片可长时间作用于皮肤,且其用于透皮给药时,药物可通过作用于皮肤上的溶胀的微针吸水后的孔道,进入皮肤微孔吸收至体内,由此增加药物在透皮给药时的生物利用度。在给药结束后,微针可被完整地取出,不会增加体内的代谢负担,并且避免了可溶材料在体内蓄积,具有良好生物安全性。
附图说明
下面结合附图对本发明的具体实施方式作进一步详细的说明。
图1示出实施例1中海藻酸钠溶胀微针的荧光显微镜图。
图2示出实施例1中海藻酸钠溶胀微针吸水后的荧光显微镜图。
图3示出实施例4、6、8中海藻酸钠溶胀微针辅助透过L-抗坏血酸的经皮渗透曲线。
图4示出实施例4、6、8中海藻酸钠溶胀微针辅助透过氨甲环酸的经皮渗透曲线。
图5示出实施例4、6、8中海藻酸钠溶胀微针辅助透过苦参碱的经皮渗透曲线。
具体实施方式
为了更清楚地说明本发明,下面结合优选实施例和附图对本发明做进一步的说明。附图中相似的部件以相同的附图标记进行表示。本领域技术人员应当理解,下面所具体描述的内容是说明性的而非限制性的,不应以此限制本发明的保护范围。
实施例1
按照表1数据,称取1g海藻酸钠粉末,溶于9mL超纯水中,为海藻酸钠溶液。称取0.112g依地酸钙钠,0.0534g葡萄糖酸内酯,溶于1mL超纯水中,为交联液。将海藻酸钠溶液与交联液共混,将共混后的溶液平铺于微针模具上,每个微针单元加入溶液体积为40μL。模具抽真空20min,吹风干燥30min后,将成型的交联海藻酸钠微针取出,在微针背部贴背衬膜。所得微针的荧光显微镜图如图1所示,所得微针吸水溶胀后的荧光显微镜图如图2所示,可知,其在吸水后仍能保持形状完整,且体积变大。
实施例2
按照表1数据,称取1g海藻酸钠粉末,溶于9mL超纯水中,为海藻酸钠溶液。称取0.224g依地酸钙钠,0.125g葡萄糖酸内酯,溶于1mL超纯水中,为交联液。将海藻酸钠溶液与交联液共混,将共混后的溶液平铺于微针模具上,每个微针单元加入溶液体积为40μL。模具抽真空20min,吹风干燥30min后,将成型的交联海藻酸钠微针取出,在微针背部贴背衬膜。
实施例3
按照表1数据,称取1.5g海藻酸钠粉末,溶于8.5mL超纯水中,为海藻酸钠溶液。称取0.281g依地酸钙钠,0.133g葡萄糖酸内酯,溶于1.5mL超纯水中,为交联液。将海藻酸钠溶液与交联液共混,将共混后的溶液平铺于微针模具上,每个微针单元加入溶液体积为40μL。模具抽真空20min,吹风干燥30min后,将成型的交联海藻酸钠微针取出,在微针背部贴背衬膜。
实施例4
按照表1数据,称取1.5g海藻酸钠粉末,溶于8.5mL超纯水中,为海藻酸钠溶液。称取0.393g依地酸钙钠,0.214g葡萄糖酸内酯,溶于1.5mL超纯水中,为交联液。将海藻酸钠溶液与交联液共混,将共混后的溶液平铺于微针模具上,每个微针单元加入溶液体积为40μL。模具抽真空20min,吹风干燥30min后,将成型的交联海藻酸钠微针取出,在微针背部贴背衬膜。
实施例5
按照表1数据,称取2g海藻酸钠粉末,溶于8mL超纯水中,为海藻酸钠溶液。称取0.449g依地酸钙钠,0.214g葡萄糖酸内酯,溶于2mL超纯水中,为交联液。将海藻酸钠溶液与交联液共混,将共混后的溶液平铺于微针模具上,每个微针单元加入溶液体积为40μL。模具抽真空20min,吹风干燥30min后,将成型的交联海藻酸钠微针取出,在微针背部贴背衬膜。
实施例6
按照表1数据,称取2g海藻酸钠粉末,溶于8mL超纯水中,为海藻酸钠溶液。称取0.598g依地酸钙钠,0.285g葡萄糖酸内酯,溶于2mL超纯水中,为交联液。将海藻酸钠溶液与交联液共混,将共混后的溶液平铺于微针模具上,每个微针单元加入溶液体积为40μL。模具抽真空20min,吹风干燥30min后,将成型的交联海藻酸钠微针取出,在微针背部贴背衬膜。
实施例7
按照表1数据,称取1g海藻酸钠粉末,溶于9mL超纯水中,为海藻酸钠溶液。称取0.561g依地酸钙钠,0.267g葡萄糖酸内酯,溶于2.5mL超纯水中,为交联液。将海藻酸钠溶液与交联液共混,将共混后的溶液平铺于微针模具上,每个微针单元加入溶液体积为40μL。模具抽真空20min,吹风干燥30min后,将成型的交联海藻酸钠微针取出,在微针背部贴背衬膜。
实施例8
按照表1数据,称取1g海藻酸钠粉末,溶于9mL超纯水中,为海藻酸钠溶液。称取0.748g依地酸钙钠,0.356g葡萄糖酸内酯,溶于2.5mL超纯水中,为交联液。将海藻酸钠溶液与交联液共混,将共混后的溶液平铺于微针模具上,每个微针单元加入溶液体积为40μL。模具抽真空20min,吹风干燥30min后,将成型的交联海藻酸钠微针取出,在微针背部贴背衬膜。
表格1 实施例1-8物质组成
对比例1
称取1g海藻酸钠粉末,溶于9mL超纯水中,为海藻酸钠溶液。称取0.561g依地酸钙钠,溶于2.5mL超纯水中,为无葡萄酸内酯的交联液。将海藻酸钠溶液与交联液共混,将共混后的溶液平铺于微针模具上,每个微针单元加入溶液体积为40μL。模具抽真空20min,吹风干燥30min后,将成型的交联海藻酸钠微针取出,在微针背部贴背衬膜。
对比例2
称取1g海藻酸钠粉末,溶于9mL超纯水中,为海藻酸钠溶液。称取0.438g乙二胺四乙酸,0.267g葡萄糖酸内酯,溶于2.5mL超纯水中,为交联液。将海藻酸钠溶液与交联液共混,将共混后的溶液平铺于微针模具上,每个微针单元加入溶液体积为40μL。模具抽真空20min,吹风干燥30min后,将成型的交联海藻酸钠微针取出,在微针背部贴背衬膜。
对比例3
称取1g海藻酸钠粉末,溶于9mL超纯水中,为海藻酸钠溶液。称取0.112g依地酸钙钠,0.0267g葡萄糖酸内酯,溶于1mL超纯水中,为交联液。此时交联液中依地酸钙钠与葡萄糖酸内酯的摩尔比为1:0.5。将海藻酸钠溶液与交联液共混,将共混后的溶液平铺于微针模具上,每个微针单元加入溶液体积为40μL。模具抽真空20min,吹风干燥30min后,将成型的交联海藻酸钠微针取出,在微针背部贴背衬膜。
对比例4
称取1g海藻酸钠粉末,溶于9mL超纯水中,为海藻酸钠溶液。称取0.561g依地酸钙钠,0.401g葡萄糖酸内酯,溶于2.5mL超纯水中,为交联液。此时交联液中依地酸钙钠与葡萄糖酸内酯的摩尔比为1:1.5。将海藻酸钠溶液与交联液共混,将共混后的溶液平铺于微针模具上,每个微针单元加入溶液体积为40μL。模具抽真空20min,吹风干燥30min后,将成型的交联海藻酸钠微针取出,在微针背部贴背衬膜。该海藻酸钠溶液与交联液的共混溶液在制作微针过程中无法保持稳定均一的黏度,导致微针单元的溶液体积不准确。制作出的微针中有肉眼可见的未溶解的依地酸钙钠与葡萄糖酸内酯颗粒。
溶胀度测试
将实施例1-8的溶胀微针干燥至恒重,测定其质量为m1,浸泡在纯水中在37℃恒温箱中浸泡至质量恒定,取出,将表面水分擦净后称重,质量记为m2,按下式计算水凝胶溶胀率:
SR=(m2-m1)/m1×100
皮肤刺激性试验
实验动物:新西兰白兔,体重2.5kg。
试验样本:每个实施例的贴剂平行选取4个样本,每个样本裁剪成直径为2cm的圆片。
试样方法:采用国家食品药品监督管理局颁发的《化学药物刺激性、过敏性和溶血性研究技术指导原则》中的有关规定和内容。将贴片贴于白兔背部单侧,7日后揭下,按照评分标准:(1)0-0.49为无刺激性;(2)0.5-2.99为轻度刺激性;(3)3.0-5.99为中度刺激性;(4)6.0-8.00为强刺激性。将所得的分数取平均值后评价贴片对皮肤的刺激性,其结果列于表2。
表格2 实施例1-8测试结果
溶胀度(%) | 皮肤刺激性 | |
实施例1 | 159.80 | 0.25(无刺激性) |
实施例2 | 137.57 | 0.25(无刺激性) |
实施例3 | 146.49 | 0.25(无刺激性) |
实施例4 | 111.04 | 0.25(无刺激性) |
实施例5 | 117.32 | 0.25(无刺激性) |
实施例6 | 109.19 | 0.5(轻刺激性) |
实施例7 | 114.16 | 0.25(无刺激性) |
实施例8 | 105.68 | 0.25(无刺激性) |
对比例1 | 0(溶解) | 0.25(无刺激性) |
对比例2 | 0(溶解) | 0.25(无刺激性) |
对比例3 | 0(崩解) | 0.25(无刺激性) |
对比例4 | 135.29(崩解) | 1.5(轻度刺激) |
其中:溶解指微针与水形成均匀相;崩解指微针在水中分散成若干个部分,与水不形成均匀相。
药物经皮渗透性试验
所用装置为美国禄根公司的SYSTEM 912-24全自动透皮扩散取样系统,所用的透皮杯的有效透过面积为0.625cm2。所使用的皮肤为新鲜的800μm厚猪耳皮肤。将各实施例的交联海藻酸钠微针应用于皮肤的角质层一侧,真皮层朝向接收池。接收池体积为2.7mL,分别对各实施例所得微针贴片进行体外经皮透过性试验。其中,实施例4、6、8做体外经皮透过性试验,对照组为单晶硅穿刺处理的皮肤和无处理皮肤。分别选用L-抗坏血酸,氨甲环酸和苦参碱作为透过药物。使用单晶硅穿刺处理过的皮肤和无处理皮肤作为对照组。曲线绘制结果如图3、图4、图5,在使用交联海藻酸钠微针作辅助透过抗坏血酸时,累计透过量为单晶硅微针对照组的2.74~2.08倍,无处理皮肤无透过。在使用交联海藻酸钠微针作辅助透过氨甲环酸时,累计透过量为单晶硅微针对照组的2.35~1.75倍,无处理皮肤无透过。在使用交联海藻酸钠微针作辅助透过苦参碱时,累计透过量为单晶硅微针对照组的1.83~1.5倍,与无处理对照组对比提升了3.16~2.68倍。
实施例1~8的24小时累积经皮渗透率如表3所示:
表格3 实施例1~8的24小时累积经皮渗透率
L-抗坏血酸(%) | 氨甲环酸(%) | 苦参碱(%) | |
实施例1 | 23.1 | 43.5 | 50.3 |
实施例2 | 26.6 | 47.8 | 55.5 |
实施例3 | 30.8 | 49.3 | 65.3 |
实施例4 | 37.6 | 55.1 | 68.1 |
实施例5 | 43.4 | 55.3 | 65.6 |
实施例6 | 46.1 | 59.2 | 61.7 |
实施例7 | 55.4 | 65.2 | 73.5 |
实施例8 | 51.5 | 71.6 | 74.7 |
单晶硅 | 17.6 | 32.1 | 40.6 |
直接透过 | 1.3 | 0 | 13.2 |
显然,本发明的上述实施例仅仅是为清楚地说明本发明所作的举例,而并非是对本发明的实施方式的限定,对于所属领域的普通技术人员来说,在上述说明的基础上还可以做出其它不同形式的变化或变动,这里无法对所有的实施方式予以穷举,凡是属于本发明的技术方案所引伸出的显而易见的变化或变动仍处于本发明的保护范围之列。
Claims (9)
1.一种不可溶的透皮微针贴片,其特征在于,包括:
微针,该微针包含基底以及位于基底上的针尖,且所述微针主要由交联的海藻酸钠构成;
背衬,与所述基底相结合,且所述背衬中与针尖相对应的部分为镂空部;
所述交联的海藻酸钠由海藻酸钠水溶液与原位交联剂的水溶液混合成均匀的水溶液后,交联而成;
所述原位交联剂为依地酸钙钠和葡萄糖酸内酯的混合;其中,所述依地酸钙钠与葡萄糖酸内酯的摩尔比为1:0.8~1:1.2;
所述原位交联剂的水溶液中,依地酸钙钠的浓度为0.3-1.0mol/L。
2.根据权利要求1所述的透皮微针贴片,其特征在于,所述海藻酸钠水溶液与原位交联剂的水溶液的体积比为20:1~4:1。
3.根据权利要求1所述的透皮微针贴片,其特征在于,所述海藻酸钠水溶液的固含量为12-25%。
4.根据权利要求1所述的透皮微针贴片,其特征在于,所述微针中还包含致孔剂。
5.根据权利要求4所述的透皮微针贴片,其特征在于,所述致孔剂的添加量占微针总重量的0.1~10wt%。
6.根据权利要求4所述的透皮微针贴片,其特征在于,所述致孔剂选自氯化钠、碳酸钠、碳酸氢钠、碳酸氢铵、聚乙烯吡咯烷酮、透明质酸及其钠盐、海藻糖、麦芽糖和环糊精中的一种或几种。
7.如权利要求1-6任一项所述的透皮微针贴片的制备方法,其特征在于,包括如下步骤:
将海藻酸钠水溶液与原位交联剂的水溶液混合,形成均匀的混合液;
将该混合液置于微针模具上,抽真空,使溶液填充模具针孔的同时完成海藻酸钠交联,干燥;
将干燥后得到的微针从模具上取下,并将基底与背衬结合。
8.如权利要求1-6任一项所述的透皮微针贴片在制备透皮给药药物中的应用。
9.根据权利要求8所述的应用,其特征在于,包括如下步骤:
将该透皮微针贴片的微针施加于人体皮肤内;
通过背衬的镂空部,向微针上施加活性物质;
待给药完毕,取出该透皮微针贴片,即可。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111073707.1A CN113797155B (zh) | 2021-09-14 | 2021-09-14 | 一种不可溶的透皮微针贴片及其制备方法和应用 |
JP2023537226A JP7529914B2 (ja) | 2021-09-14 | 2022-08-18 | 不溶性の経皮マイクロニードルパッチ及びその調製方法並びに応用 |
PCT/CN2022/113262 WO2023040568A1 (zh) | 2021-09-14 | 2022-08-18 | 一种不可溶的透皮微针贴片及其制备方法和应用 |
US18/329,399 US11801373B1 (en) | 2021-09-14 | 2023-06-05 | Insoluble transdermal microneedle patch, and preparation method therefor and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111073707.1A CN113797155B (zh) | 2021-09-14 | 2021-09-14 | 一种不可溶的透皮微针贴片及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113797155A CN113797155A (zh) | 2021-12-17 |
CN113797155B true CN113797155B (zh) | 2023-06-20 |
Family
ID=78895205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111073707.1A Active CN113797155B (zh) | 2021-09-14 | 2021-09-14 | 一种不可溶的透皮微针贴片及其制备方法和应用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US11801373B1 (zh) |
JP (1) | JP7529914B2 (zh) |
CN (1) | CN113797155B (zh) |
WO (1) | WO2023040568A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113797155B (zh) * | 2021-09-14 | 2023-06-20 | 中国科学院理化技术研究所 | 一种不可溶的透皮微针贴片及其制备方法和应用 |
CN115337272B (zh) * | 2022-07-15 | 2023-08-04 | 汕头大学 | 一种天然多糖基化学-物理双交联水凝胶微粒及其制备与应用 |
CN115154883B (zh) * | 2022-07-27 | 2024-05-03 | 武汉理工大学三亚科教创新园 | 一种可更换载药储层的水凝胶微针及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107412201B (zh) * | 2017-05-22 | 2020-06-19 | 莎穆(上海)生物科技有限公司 | 一种葡萄糖响应性艾塞那肽微针贴片及其制备方法 |
CN108578888A (zh) * | 2018-02-07 | 2018-09-28 | 佛山市顺德区中山大学研究院 | 一种透皮输送活性益生菌的可溶性微针阵列贴片及其制备方法和应用 |
US11318292B2 (en) * | 2018-05-28 | 2022-05-03 | Microneedles Inc. | Microneedle patch for transdermal injections |
CN109364366A (zh) * | 2018-09-21 | 2019-02-22 | 华中科技大学 | 模板法制备多孔聚合物微针的方法及其应用 |
CN113797155B (zh) * | 2021-09-14 | 2023-06-20 | 中国科学院理化技术研究所 | 一种不可溶的透皮微针贴片及其制备方法和应用 |
-
2021
- 2021-09-14 CN CN202111073707.1A patent/CN113797155B/zh active Active
-
2022
- 2022-08-18 WO PCT/CN2022/113262 patent/WO2023040568A1/zh active Application Filing
- 2022-08-18 JP JP2023537226A patent/JP7529914B2/ja active Active
-
2023
- 2023-06-05 US US18/329,399 patent/US11801373B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN113797155A (zh) | 2021-12-17 |
JP2024500424A (ja) | 2024-01-09 |
US11801373B1 (en) | 2023-10-31 |
US20230347124A1 (en) | 2023-11-02 |
JP7529914B2 (ja) | 2024-08-06 |
WO2023040568A1 (zh) | 2023-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN113797155B (zh) | 一种不可溶的透皮微针贴片及其制备方法和应用 | |
CN111388407B (zh) | 一种基于多巴胺凝胶的微针阵列及其制备和应用 | |
AU2017394923B2 (en) | Methods and systems for treating a site of a medical implant | |
KR101400545B1 (ko) | 마이크로니들 디바이스 및 그의 제조 방법 | |
CN105078880A (zh) | 一种用于多肽和蛋白质类药物透皮给药的高分子可溶微针及其制备方法 | |
EP3626234A1 (en) | Microneedle percutaneous patch containing donepezil | |
CN108434125B (zh) | 一种介孔二氧化硅-胰岛素纳米缓释经皮贴剂的制备方法 | |
CN107007927A (zh) | 一种基于电场驱动给药的微针阵列药贴及制备方法 | |
CN110812688B (zh) | 一种透皮给药的微针及其制备方法 | |
WO2016155082A1 (zh) | 一种溶胀型丝素蛋白微针给药系统及其制备方法 | |
CN102078636A (zh) | 含重组人表皮生长因子的水凝胶敷料及其制备方法与应用 | |
WO2021047628A1 (zh) | 一种缓释微针贴片及其制备方法 | |
CN105879213A (zh) | 生物可降解硫酸钙/明胶复合微针阵列贴片及其制备方法 | |
CN114805713A (zh) | 一种水凝胶、微针及其制备方法和应用 | |
CN105617526A (zh) | 一种溶胀型丝素蛋白微针给药系统及其制备方法 | |
CN106540315B (zh) | 一种喷涂型壳聚糖水剂创伤敷料的制备方法 | |
CN114917465B (zh) | 一种自发热微针载药贴片及其制备方法 | |
CN114834066B (zh) | 复合多层微针的制备方法 | |
CN105902483A (zh) | 一种温敏经皮给药材料的制备方法 | |
CN113679657A (zh) | 用于治疗失眠的丝素蛋白微针透皮贴片及其制备方法 | |
CN113368034B (zh) | 败血症治疗用可溶性微针贴片及其制作方法 | |
CN113995951B (zh) | 用于ha可溶性微针的ha材料制备方法及其应用 | |
CN115869242B (zh) | 一种药物促渗水凝胶敷料及其制备方法与应用 | |
CN114404366B (zh) | 苦参总碱透皮吸收纳米微乳 | |
CN116440062B (zh) | 一种搭载左西孟旦用于治疗心力衰竭的可溶性微针贴片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |